BioNexus Gene Lab Corp. (BGLC) Total liabilities 2018–2025
BioNexus Gene Lab Corp. (BGLC) total liabilities at each fiscal year-end, per SEC filings.
$637,856FY2025 · since FY2018: $130,313 → $637,856
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $637,856 | -69.8% |
| FY2024 | $2.1M | +21.2% |
| FY2023 | $1.7M | -16.1% |
| FY2022 | $2.1M | -13.3% |
| FY2021 | $2.4M | -30.7% |
| FY2020 | $3.5M | +3071.7% |
| FY2019 | $108,872 | -16.5% |
| FY2018 | $130,313 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Gross marginBGLC Operating incomeBGLC Operating marginBGLC Operating cash flowBGLC Free cash flowBGLC Capital expendituresBGLC Return on equityBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Shareholders’ equityBGLC overview →